As of 2025-07-15, the EV/EBITDA ratio of Chinook Therapeutics Inc (KDNY) is -11.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KDNY's latest enterprise value is 2,773.05 mil USD. KDNY's TTM EBITDA according to its financial statements is -233.23 mil USD. Dividing these 2 quantities gives us the above KDNY EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.3x - 13.6x | 13.4x |
| Forward P/E multiples | 17.3x - 32.2x | 20.6x |
| Fair Price | (54.49) - (42.27) | (53.45) |
| Upside | -234.9% - -204.7% | -232.3% |
| Date | EV/EBITDA |